FDA Brief

Warning letters Devices

FDA warning letter to

ExThera Medical Corporation

High riskIssued Feb 6Posted Feb 24Center for Devices and Radiological Health

ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.

What happened

FDA inspected ExThera from May 27, 2025, to June 4, 2025, as sponsor of two significant-risk investigational device exemption (IDE) studies. FDA found devices shipped for compassionate use without prior approval, no evidence that informed consent was verified for enrolled subjects, and public promotion of Seraph 100 as approved, safe, and effective even though it lacks premarket approval (PMA). FDA also cited the device as adulterated and misbranded based on its website and public statements.

What FDA found

  1. The company shipped Seraph 100 devices for compassionate use, an unapproved treatment pathway, before getting FDA approval for the change to the study plan and did not report one emergency use as required.

    21 CFR 812.35(a)(1)
  2. The company did not properly monitor the studies or secure investigator compliance, and it could not provide evidence that informed consent was signed for enrolled subjects.

    21 CFR 812.40; 21 CFR 812.46(a)
  3. FDA says Seraph 100 is adulterated because ExThera lacks an approved premarket approval (PMA) or IDE for the device as marketed.

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  4. FDA says the device is misbranded because ExThera did not submit the required premarket notification (510(k)) before commercial distribution.

    section 502(o) of the Act, 21 U.S.C. § 352(o); 21 CFR 807.81
  5. FDA says ExThera made false or misleading statements about the device’s regulatory status.

    section 502(a) of the Act, 21 U.S.C. § 352(a)
  6. FDA found the website claimed a safety profile consistent with standard extracorporeal labeling even though FDA had not determined the device safe for U.S. patients.

    21 CFR 812.5(b); 21 CFR 812.7

What FDA wants

Within 15 working days, send FDA documentation of corrective and preventive actions, with completion dates and a plan to check effectiveness. FDA also asks ExThera to stop activities that misbrand or adulterate Seraph 100, revise its compassionate-use instruction, and account for distributed devices.

Who should pay attention

  • clinical study sponsors and institutional review boards
  • distributors or partners of investigational medical devices
  • companies making promotional claims about unapproved devices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk